CBIO FY 2020 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$337M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M

Gross Profit

$10M100.0% margin

Operating Income

-$52M-506.8% margin

Net Income

-$51M-502.1% margin

EPS (Diluted)

$-1.12

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$39M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$143M

Total Liabilities

$15M

Stockholders' Equity

$128M

Cash & Equivalents

$137M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$0	—
Gross Profit	$10M	-$899,302	+1230.1%
Operating Income	-$52M	-$61M	+16.1%
Net Income	-$51M	-$54M	+5.7%